Mustang Bio Announces FDA Acceptance of IND Application for MB-109

Mustang Bio announced that the FDA accepted its Investigational New Drug application for MB-109, a novel combination of the company’s MB-101 and MB-108 assets. The candidate is intended to treat recurrent glioblastoma and high-grade astrocytoma. The announcement was reported on October 30, 2026.